Quest Diagnostics, Inc. (NYSE: DGX) is 8.57% higher on its value in year-to-date trading and has touched a low of $119.59 and a high of $152.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The DGX stock was last observed hovering at around $149.85 in the last trading session, with the day’s loss setting it -0.16%.
Currently trading at $149.69, the stock is 2.21% and 4.81% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.69 million and changing -0.11% at the moment leaves the stock 10.42% off its SMA200. DGX registered 12.10% gain for a year compared to 6-month gain of 17.20%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 0.81% loss in the last 1 month and extending the period to 3 months gives it a 6.33%, and is -0.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.44% over the week and 2.39% over the month.
Quest Diagnostics, Inc. (DGX) has around 48000 employees, a market worth around $16.66B and $9.35B in sales. Current P/E ratio is 20.19 and Fwd P/E is 15.59. Profit margin for the company is 8.95%. Distance from 52-week low is 25.17% and -1.52% from its 52-week high. The company has generated returns on investments over the last 12 months (7.64%).
The EPS is expected to grow by 2.24% this year
1203.0 institutions hold shares in Quest Diagnostics, Inc. (DGX), with institutional investors hold 91.90% of the company’s shares. The shares outstanding are 111.00M, and float is at 110.77M with Short Float at 2.11%. Institutions hold 91.50% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 13.92 million shares valued at $$1.85 billion. The investor’s holdings represent 12.5423 of the DGX Shares outstanding. As of 2024-03-31, the second largest holder is BLACKROCK INC. with 10.7 million shares valued at $$1.42 billion to account for 9.6402 of the shares outstanding. The other top investors are STATE STREET CORP which holds 5.2 million shares representing 4.684 and valued at over $$692.06 million, while VICTORY CAPITAL MANAGEMENT INC holds 3.5336 of the shares totaling 3.92 million with a market value of $$522.1 million.
Quest Diagnostics, Inc. (DGX) Insider Activity
The most recent transaction is an insider sale by DELANEY MARK E, the company’s SVP & Chief Commercial Officer. SEC filings show that DELANEY MARK E sold 420 shares of the company’s common stock on Jul 24 ’24 at a price of $143.08 per share for a total of $60094.0. Following the sale, the insider now owns 5019.0 shares.
Quest Diagnostics, Inc. disclosed in a document filed with the SEC on Apr 29 ’24 that KUPPUSAMY KARTHIK (SVP, Clinical Solutions) sold a total of 1,760 shares of the company’s common stock. The trade occurred on Apr 29 ’24 and was made at $140.00 per share for $0.25 million. Following the transaction, the insider now directly holds 13435.0 shares of the DGX stock.
Still, SEC filings show that on Feb 28 ’24, Doherty Catherine T. (EVP, Regional Businesses) disposed off 5,557 shares at an average price of $126.57 for $0.7 million. The insider now directly holds 69,599 shares of Quest Diagnostics, Inc. (DGX).
